Literature DB >> 21544060

Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury.

Brandon Renner1, Viviana P Ferreira, Claudio Cortes, Ryan Goldberg, Danica Ljubanovic, Michael K Pangburn, Matthew C Pickering, Stephen Tomlinson, Amanda Holland-Neidermyer, Derek Strassheim, V Michael Holers, Joshua M Thurman.   

Abstract

Factor H is a regulator of the alternative pathway of complement, and genetic studies have shown that patients with mutations in factor H are at increased risk for several types of renal disease. Pathogenic activation of the alternative pathway in acquired diseases, such as ischemic acute kidney injury, suggests that native factor H has a limited capacity to control the alternative pathway in the kidney. Here we found that an absolute deficiency of factor H produced by gene deletion prevented complement activation on tubulointerstitial cells after ischemia/reperfusion (I/R) injury, likely because alternative pathway proteins were consumed in the fluid phase. In contrast, when fluid-phase regulation by factor H was maintained while the interaction of factor H with cell surfaces was blocked by a recombinant inhibitor protein, complement activation after renal I/R increased. Finally, a recombinant form of factor H, specifically targeted to sites of C3 deposition, reduced complement activation in the tubulointerstitium after ischemic injury. Thus, although factor H does not fully prevent activation of the alternative pathway of complement on ischemic tubules, its interaction with the tubule epithelial cell surface is critical for limiting complement activation and attenuating renal injury after ischemia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21544060      PMCID: PMC3133686          DOI: 10.1038/ki.2011.115

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  26 in total

Review 1.  The central role of the alternative complement pathway in human disease.

Authors:  Joshua M Thurman; V Michael Holers
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

Review 2.  Separation of self from non-self in the complement system: a role for membrane cofactor protein and decay accelerating factor.

Authors:  J P Atkinson; T J Oglesby; D White; E A Adams; M K Liszewski
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

3.  Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies.

Authors:  Hong Xiao; Adrian Schreiber; Peter Heeringa; Ronald J Falk; J Charles Jennette
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

Review 4.  The simple design of complement factor H: Looks can be deceiving.

Authors:  Jessy J Alexander; Richard J Quigg
Journal:  Mol Immunol       Date:  2006-08-17       Impact factor: 4.407

5.  Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection.

Authors:  Carl Atkinson; Hongbin Song; Bo Lu; Fei Qiao; Tara A Burns; V Michael Holers; George C Tsokos; Stephen Tomlinson
Journal:  J Clin Invest       Date:  2005-08-25       Impact factor: 14.808

6.  Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion.

Authors:  Joshua M Thurman; Danica Ljubanović; Pamela A Royer; Damian M Kraus; Hector Molina; Nicholas P Barry; Gregory Proctor; Moshe Levi; V Michael Holers
Journal:  J Clin Invest       Date:  2006-01-26       Impact factor: 14.808

7.  A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2.

Authors:  H Molina; T Kinoshita; K Inoue; J C Carel; V M Holers
Journal:  J Immunol       Date:  1990-11-01       Impact factor: 5.422

8.  Treatment with an inhibitory monoclonal antibody to mouse factor B protects mice from induction of apoptosis and renal ischemia/reperfusion injury.

Authors:  Joshua M Thurman; Pamela A Royer; Danica Ljubanovic; Belda Dursun; Amanda M Lenderink; Charles L Edelstein; V Michael Holers
Journal:  J Am Soc Nephrol       Date:  2006-02-08       Impact factor: 10.121

9.  Critical role of the C-terminal domains of factor H in regulating complement activation at cell surfaces.

Authors:  Viviana P Ferreira; Andrew P Herbert; Henry G Hocking; Paul N Barlow; Michael K Pangburn
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

10.  Local extravascular pool of C3 is a determinant of postischemic acute renal failure.

Authors:  Conrad A Farrar; Wuding Zhou; Tao Lin; Steven H Sacks
Journal:  FASEB J       Date:  2006-02       Impact factor: 5.191

View more
  30 in total

1.  Efficacy of Targeted Complement Inhibition in Experimental C3 Glomerulopathy.

Authors:  Marieta M Ruseva; Tao Peng; Melissa A Lasaro; Keith Bouchard; Susan Liu-Chen; Fang Sun; Zhao-Xue Yu; Andre Marozsan; Yi Wang; Matthew C Pickering
Journal:  J Am Soc Nephrol       Date:  2015-06-05       Impact factor: 10.121

2.  Essential role of surface-bound complement factor H in controlling immune complex-induced arthritis.

Authors:  Nirmal K Banda; Gaurav Mehta; Viviana P Ferreira; Claudio Cortes; Matthew C Pickering; Michael K Pangburn; William P Arend; V Michael Holers
Journal:  J Immunol       Date:  2013-02-22       Impact factor: 5.422

3.  Factor h and properdin recognize different epitopes on renal tubular epithelial heparan sulfate.

Authors:  Azadeh Zaferani; Romain R Vivès; Pieter van der Pol; Gerjan J Navis; Mohamed R Daha; Cees van Kooten; Hugues Lortat-Jacob; Marc A Seelen; Jacob van den Born
Journal:  J Biol Chem       Date:  2012-07-19       Impact factor: 5.157

Review 4.  Complement as a multifaceted modulator of kidney transplant injury.

Authors:  Paolo Cravedi; Peter S Heeger
Journal:  J Clin Invest       Date:  2014-06-02       Impact factor: 14.808

5.  Modulation of the Alternative Pathway of Complement by Murine Factor H-Related Proteins.

Authors:  Alexandra H Antonioli; Janice White; Frances Crawford; Brandon Renner; Kevin J Marchbank; Jonathan P Hannan; Joshua M Thurman; Philippa Marrack; V Michael Holers
Journal:  J Immunol       Date:  2017-11-29       Impact factor: 5.422

6.  Complement Inhibitor CRIg/FH Ameliorates Renal Ischemia Reperfusion Injury via Activation of PI3K/AKT Signaling.

Authors:  Chao Hu; Long Li; Peipei Ding; Ling Li; Xiaowen Ge; Long Zheng; Xuanchuan Wang; Jina Wang; Weitao Zhang; Na Wang; Hongyu Gu; Fan Zhong; Ming Xu; Ruiming Rong; Tongyu Zhu; Weiguo Hu
Journal:  J Immunol       Date:  2018-11-14       Impact factor: 5.422

7.  Donor Urinary C5a Levels Independently Correlate With Posttransplant Delayed Graft Function.

Authors:  Bernd Schröppel; Peter S Heeger; Heather Thiessen-Philbrook; Isaac E Hall; Mona D Doshi; Francis L Weng; Peter P Reese; Chirag R Parikh
Journal:  Transplantation       Date:  2019-01       Impact factor: 4.939

8.  Detection of complement activation using monoclonal antibodies against C3d.

Authors:  Joshua M Thurman; Liudmila Kulik; Heather Orth; Maria Wong; Brandon Renner; Siranush A Sargsyan; Lynne M Mitchell; Dennis E Hourcade; Jonathan P Hannan; James M Kovacs; Beth Coughlin; Alex S Woodell; Matthew C Pickering; Bärbel Rohrer; V Michael Holers
Journal:  J Clin Invest       Date:  2013-04-24       Impact factor: 14.808

9.  Identification of a novel mode of complement activation on stimulated platelets mediated by properdin and C3(H2O).

Authors:  Gurpanna Saggu; Claudio Cortes; Heather N Emch; Galia Ramirez; Randall G Worth; Viviana P Ferreira
Journal:  J Immunol       Date:  2013-05-15       Impact factor: 5.422

10.  Properdin-Mediated C5a Production Enhances Stable Binding of Platelets to Granulocytes in Human Whole Blood.

Authors:  Adam Z Blatt; Gurpanna Saggu; Koustubh V Kulkarni; Claudio Cortes; Joshua M Thurman; Daniel Ricklin; John D Lambris; Jesus G Valenzuela; Viviana P Ferreira
Journal:  J Immunol       Date:  2016-04-25       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.